RedHill Biopharma Ltd – (NASDAQ:RDHL) Given Average Rating of “Buy” by Brokerages
RedHill Biopharma Ltd – (NASDAQ:RDHL) has earned an average rating of “Buy” from the seven brokerages that are covering the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $28.00.
Several equities research analysts have weighed in on RDHL shares. Zacks Investment Research upgraded RedHill Biopharma Ltd – from a “sell” rating to a “hold” rating in a report on Friday, August 26th. FBR & Co upped their target price on RedHill Biopharma Ltd – from $33.00 to $36.00 and gave the stock an “outperform” rating in a report on Wednesday, July 27th.
RedHill Biopharma Ltd – (NASDAQ:RDHL) traded down 0.327% during midday trading on Wednesday, hitting $14.652. The company had a trading volume of 19,252 shares. RedHill Biopharma Ltd – has a 52 week low of $8.10 and a 52 week high of $16.54. The stock’s market capitalization is $186.58 million. The stock has a 50 day moving average price of $15.12 and a 200-day moving average price of $12.55.
RedHill Biopharma Ltd – (NASDAQ:RDHL) last posted its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.52. On average, equities analysts predict that RedHill Biopharma Ltd – will post ($2.06) EPS for the current year.
Large investors have recently modified their holdings of the company. Van ECK Associates Corp boosted its stake in shares of RedHill Biopharma Ltd – by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock worth $105,000 after buying an additional 138 shares during the period. Ingalls & Snyder LLC bought a new stake in shares of RedHill Biopharma Ltd – during the second quarter worth $451,000. Oppenheimer & Co. Inc. bought a new stake in shares of RedHill Biopharma Ltd – during the second quarter worth $142,000. Finally, Royal Bank of Canada boosted its stake in shares of RedHill Biopharma Ltd – by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock worth $259,000 after buying an additional 191 shares during the period.
About RedHill Biopharma Ltd –
Receive News & Ratings for RedHill Biopharma Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd - and related companies with MarketBeat.com's FREE daily email newsletter.